Total Payments
$10,513
2024 Payments
$2,320
Companies
46
Transactions
678
Medicare Patients
17,765
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$10,388 (98.8%)
Education$125.31 (1.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,388 | 672 | 98.8% |
| Education | $125.31 | 6 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,803 | 103 | $0 (2024) |
| Novo Nordisk Inc | $1,395 | 91 | $0 (2024) |
| ABBVIE INC. | $751.71 | 55 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $631.47 | 54 | $0 (2023) |
| Lilly USA, LLC | $627.10 | 51 | $0 (2024) |
| GlaxoSmithKline, LLC. | $594.67 | 54 | $0 (2024) |
| Abbott Laboratories | $558.18 | 26 | $0 (2024) |
| Amarin Pharma Inc. | $486.51 | 30 | $0 (2022) |
| Merck Sharp & Dohme LLC | $397.62 | 27 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $296.24 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,320 | 126 | AstraZeneca Pharmaceuticals LP ($415.90) |
| 2023 | $2,184 | 128 | AstraZeneca Pharmaceuticals LP ($387.37) |
| 2022 | $2,007 | 127 | AstraZeneca Pharmaceuticals LP ($465.56) |
| 2021 | $2,252 | 159 | AstraZeneca Pharmaceuticals LP ($341.81) |
| 2020 | $1,269 | 106 | Janssen Pharmaceuticals, Inc ($228.81) |
| 2019 | $468.06 | 31 | Novo Nordisk Inc ($185.61) |
| 2018 | $12.96 | 1 | Novo Nordisk Inc ($12.96) |
All Payment Transactions
678 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.02 | General |
| Category: Cardio-renal | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $26.67 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $1.38 | General |
| Category: Diabetes | ||||||
| 12/04/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: Endocrinology | ||||||
| 12/04/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $31.77 | General |
| Category: Diabetes | ||||||
| 11/27/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: RESPIRATORY | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.21 | General |
| Category: Cardiovascular | ||||||
| 11/20/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: PSYCHIATRY | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.41 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $105.12 | General |
| Category: Respiratory | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/21/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: NEUROSCIENCE | ||||||
| 10/17/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Diabetes Care | ||||||
| 10/17/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: Neurology | ||||||
| 10/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: Diabetes | ||||||
| 10/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Respiratory | ||||||
| 10/08/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: Inflammation | ||||||
| 09/30/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Psychology/Psychiatric | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 4,364 | 7,432 | $846,363 | $381,625 |
| 2022 | 25 | 4,201 | 7,220 | $777,129 | $352,449 |
| 2021 | 28 | 4,621 | 7,992 | $884,854 | $399,144 |
| 2020 | 29 | 4,579 | 7,870 | $890,058 | $331,873 |
Total Patients
17,765
Total Services
30,514
Medicare Billing
$1.5M
Procedure Codes
105
All Medicare Procedures & Services
105 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 739 | 1,885 | $275,210 | $113,377 | 41.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 695 | 695 | $162,630 | $88,117 | 54.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 618 | 1,012 | $217,580 | $80,162 | 36.8% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 367 | 367 | $40,515 | $27,746 | 68.5% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 102 | 120 | $52,440 | $25,500 | 48.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 410 | 410 | $16,400 | $12,331 | 75.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 653 | 888 | $15,096 | $5,233 | 34.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 276 | 580 | $5,800 | $4,864 | 83.9% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 15 | 527 | $12,648 | $4,440 | 35.1% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 49 | 98 | $7,350 | $3,423 | 46.6% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 20 | 20 | $6,540 | $3,205 | 49.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 16 | 16 | $5,344 | $2,601 | 48.7% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 13 | 13 | $4,472 | $2,109 | 47.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 29 | 29 | $6,264 | $1,806 | 28.8% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 49 | 49 | $2,460 | $1,641 | 66.7% |
| 85610 | Blood test, clotting time | Office | 2023 | 36 | 290 | $3,190 | $1,214 | 38.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 56 | 117 | $5,967 | $1,121 | 18.8% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 28 | 56 | $1,848 | $875.88 | 47.4% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 20 | 20 | $1,100 | $811.00 | 73.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 72 | 76 | $2,584 | $772.02 | 29.9% |
| 81002 | Urinalysis, manual test | Office | 2023 | 45 | 50 | $400.00 | $170.50 | 42.6% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 20 | 69 | $345.00 | $73.80 | 21.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 36 | 45 | $180.00 | $31.38 | 17.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 716 | 1,820 | $265,720 | $110,004 | 41.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 657 | 657 | $153,738 | $86,115 | 56.0% |
About Dr. Barry Brown, DO
Dr. Barry Brown, DO is a Internal Medicine healthcare provider based in Low Moor, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184628737.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barry Brown, DO has received a total of $10,513 in payments from pharmaceutical and medical device companies, with $2,320 received in 2024. These payments were reported across 678 transactions from 46 companies. The most common payment nature is "Food and Beverage" ($10,388).
As a Medicare-enrolled provider, Brown has provided services to 17,765 Medicare beneficiaries, totaling 30,514 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 105 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Low Moor, VA
- Active Since 06/10/2005
- Last Updated 07/27/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1184628737
Products in Payments
- FARXIGA (Drug) $1,028
- Ozempic (Drug) $835.97
- XARELTO (Drug) $563.78
- BREZTRI (Drug) $501.39
- Vascepa (Drug) $486.51
- TRELEGY ELLIPTA (Drug) $447.97
- FREESTYLE LIBRE 3 (Device) $420.59
- ELIQUIS (Drug) $370.55
- REXULTI (Drug) $359.35
- JARDIANCE (Drug) $318.42
- VRAYLAR (Drug) $284.64
- UBRELVY (Drug) $263.34
- BELSOMRA (Drug) $262.22
- XIFAXAN (Drug) $244.66
- Rybelsus (Drug) $237.94
- MOUNJARO (Drug) $217.44
- TRULICITY (Drug) $203.47
- QULIPTA (Drug) $178.56
- NEXLETOL (Drug) $163.05
- AIRSUPRA (Drug) $160.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.